MarketPulse
I

$ICLR

6 articles found
3 positive
2 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Clinical Trial Data Visualization Market to Double by 2030 Amid AI Surge

Clinical trial data visualization market projected to grow from $0.89B (2025) to $1.82B (2030) at 15.4% CAGR, driven by AI adoption and decentralized trials.
ORCLORCLpDTMOIQVICLRcloud-based solutionsdecentralized trials
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Clinical Trials Tech Market Set to Surge 59% to $81.46B by 2030

Clinical trials tech market projected to grow 59% from $51.15B (2025) to $81.46B (2030) at 9.8% CAGR, driven by AI, decentralized models, and digital transformation.
ORCLORCLpDIBMIQVICLRclinical trialsAI adoption
GlobeNewswire Inc.GlobeNewswire Inc.··Kirby Mcinerney Llp

ICON Public Limited Company Under Internal Investigation Over Revenue Recognition Controls

ICON's Audit Committee investigates revenue recognition control deficiencies from 2023-2025. Stock plunged 40% after disclosure; company delayed financials and withdrew 2025 guidance.
ICLRsecurities fraudshareholder lawsuit
BenzingaBenzinga··Vandana Singh

J&J Receives FDA Breakthrough Designation for Rybrevant Faspro in HPV-Negative Head and Neck Cancer

FDA grants J&J's Rybrevant Faspro breakthrough designation for HPV-negative head and neck cancer, potentially accelerating patient access to this new treatment option.
JNJMRKSNYTAKICLRclinical trialimmunotherapy
GlobeNewswire Inc.GlobeNewswire Inc.··Towards Healthcare

Clinical Trial Software Market to Nearly Triple to $34.15B by 2035

Clinical trial software market projected to nearly triple to $34.15B by 2035, driven by pharmaceutical industry's digital transformation and increased adoption of AI-enabled solutions.
ORCLORCLpDTMOIQVVEEV+1regulatory compliancecloud-based solutions
GlobeNewswire Inc.GlobeNewswire Inc.··Block & Leviton Llp

Law Firm Launches Investigation Into GEMI Executive Departures

Law firm Block & Leviton investigates GEMI for potential securities violations after three senior executives departed amid 10% stock decline and 25% workforce reduction.
CVNAGEMIICLRsecurities fraudclass action lawsuit